Institut Pasteur

Other

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique-cnrs

Inserm

Alain Israel

Gilles Courtois

Shoji Yamaoka

Francois Traincard

Fabrice Agou

Michel Veron

Arnold Munnich

Richard A Lewis

Yves-Marie Coic

Annemarie Poustka

David L Nelson

Nina Heiss

Robert Weil

Moise Levy

Swaroop Aradhya

Asmae Smahi

Michele D'Urso

Sue J Kenwrick

Hayley Woffendin

Michel Vernon

Yves-Marie Coiec

François Traincard

Yves-Marie COÏC

The present invention relates to polypeptides that inhibit the NF-&#x3ba;B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.

Methods of identifying NF-&#x3ba;B inhibitors

The present invention relates to polypeptides that inhibit the NF-&kgr;B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.

Selective inhibition of NF-&#x3ba;B activation by peptides designed to disrupt nemo oligomerization

NF-&#x3ba;B peptides designed to disrupt NEMO oligomerization

Incontinentia Pigmenti (IP) is a neurocutaneous genodermatosis that segregates as an X-linked dominant disorder with a high probability of prenatal male lethality. A locus in Xq28 containing NF-&kgr;B Essential Modulator, a gene product involved in the activation of NF-kB and central to many pro-inflammatory and apoptotic pathways, contains mutations in the majority of cases of IP. Disclosed are methods, compositions and kits directed to a defect in a NF-&kgr;B related disease such as IP.

Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-&kgr;B) activation

The present invention relates to nucleotide sequences encoding a modulator of NF-&kgr;B, and to the polypeptides encoded by the nucleotide sequences. In particular, the invention relates to nucleotide sequences and the polypeptides encoded thereby, wherein the polypeptides are involved in the response to NF-&kgr;B-activating stimuli, including HTLV-1 Tax, LPS, PMA and IL-1. The invention also relates to antibodies to the modulator of NF-&kgr;B, methods of detecting modulator of NF-&kgr;B using the antibodies, methods of treatment associated with NF-&kgr;B activation and to methods of identifying compounds which modulate the activity of the modulator of NF-&kgr;B.

Nucleotide sequence encoding a modulator of NF-&kgr;B

Growing community of inventors

Paris, France

Alain Israel